Anti-Migraine Drugs: Market Research Report

February 2010 | 580 pages | ID: A431247D60EEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the US And European markets for Anti-Migraine Drugs in US$ Million.

Annual forecasts are provided for the period 2006 through 2015.

A six-year historic Analysis is also provided for these markets.

The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., Eisai, Inc., Eisai, Inc, Johnson & Johnson, Inc., Kowa Pharmaceuticals America, Inc., MAP Pharmaceuticals, Inc., Merck & Co., Inc., Merck & Co., Inc., Poze, Poze., Winston Pharmaceuticals, Inc., Wyeth Consumer Healthcare, Zogenix, Inc., AstraZeneca Plc, Bayer AG, Ethypharm S.A., GlaxoSmithKline Plc, Meda AB, Novartis AG, and Novartis AG.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II-A. A US AND EUROPEAN MARKET REPORT

1.MIGRAINE: AN OVERVIEW

What is Migraine?
What Causes Migraine?
Migraine Classification
Migraine with Aura
Migraine without Aura
Aura without Headache
Abdominal Migraine
Facial Migraine
Basilar Migraine
Familial Hemiplegic Migraine
Ophthalmoplegic/Ocular Migraine
Retinal Migraine
Menstrual Migraine
Status Migraine
Migraine Attack Stages
I – The Prodrome Stage
II – The Aura Stage
III – The Headache Stage
IV – The Postdrome Stage

2.ANTI-MIGRAINE TREATMENT

Historical Perspective
Migraine Treatment
Abortive Drugs
Selective Serotonin Receptor (5- HTI) Agonists/ Triptans
Triptans Approved for the Treatment of Migraine
Ergot Alkaloids
Ergot Alkaloids for the Treatment of Migraine
Antiemetics
Antiemetics for the Treatment of Migraine
Analgesics
Analgesics for the Treatment of Migraine
Prophylactic Drugs
Beta-Blockers
Calcium Channel Blockers
Anticonvulsants
Tricyclic Antidepressants
Non-steroidal Anti-inflammatory Drugs
Selective Serotonin Reuptake Inhibitors
Serotonin Antagonists
Anti-migraine Drugs: Side Effects
Abortive Drugs: Side Effects
Prophylactic Drugs: Side Effects
Anti-migraine Drugs: Interactions
Abortive Medications: Interactions
Prophylactic Drugs: Interactions

3.RESEARCH & DEVELOPMENT

Pipeline Drug Research
Pipeline Drug Candidates in Phase III Clinical Trials
Pipeline Drug Candidates in Phase II Clinical Trials
Clinical Research / Drug Development Initiatives
MAP Pharma Announces Positive Phase III Results for Levadex
Addex Initiates Phase IIb Trials for ADX 10059
Asterand and BTG Announce Plans to Commence Phase IIa Trials
Alexza Commences Phase IIb Trials of AZ-104
Neuralieve Announces Trial Completion of New Migraine Treatment Device
NeurAxon Announces Encouraging Results of Phase 2 Trials
Roxro Pharma Announces ROX-828 Results
Merck Announces Encouraging Results of Phase III Study of Telcagepant
ProEthic Pharmaceuticals Reports Encouraging Phase III Results
Recent Migraine Research
Study Reveals Cocoa Consumption to Ease Migraine
Study Reveals Women with Migraine to be At Lesser Risk of Breast Cancer
Study Shows Risk of Migraine to be Less Among High Blood Pressure Patients

II-B. REGIONAL MARKET PERSPECTIVE

1.THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis
Migraine – Prevalence and Economic Burden
Anti-Migraine Drugs Market At A Glance
Triptans – Leading the Anti-Migraine Treatment Race
Generic Imitrex Make Foray
Botox – An Emerging Option for Migraine Prophylaxis
Anti-migraine Drugs – Limitations Abound
The Quest to Unravel the Mystery of Cause of Migraine Continues…
Strategic Corporate Developments
Zogenix, Astellas Pharma Sign Agreement for Sumavel DosePro
Kowa Pharma to Divest Diclofenac Franchise
Zogenix Wins FDA Approval for Sumavel DosePro
Orchid Pharma Obtains FDA Approval for Sumatriptan Succinate Tablets
Sandoz Unveils Sumatriptan and Calcitonin- Salmon Nasal Spray
Wockhardt to Introduce Divalproex ER
Ranbaxy Receives FDA Approval for Imitrex Generic
Kowa America Secures FDA Approval for Cambia
Almirall Receives FDA Approval for Axert/ Almogran
Wockhardt Receives FDA Approval for Sumatriptan Injections
Teva Pharmaceutical Secures Approval, Launches Imitrex Generic
AstraZeneca Unveils Zomig Rapimeltt in 5 mg Dosage Strength
Bedford Laboratories Launches Sumatriptan Succinate Injection
Ipca Laboratories and Heritage Pharmaceuticals Announce Strategic Alliance
Dr. Reddy's Introduces Approved Imitrex® Generic
US FDA Approves Divalproex Sodium Tablets
GSK and Pozen Announce FDA Approval for Treximet
Aurobindo Wins Provisionary Approval for Sumatriptan Succinate Tablets
Par Pharmaceuticals to Commence Shipment of Imitrex’s Generic Version
Select Players
Abbott Laboratories, Inc.
Eisai, Inc.
Eli Lilly and Company
Johnson & Johnson, Inc.
Kowa Pharmaceuticals America, Inc.
MAP Pharmaceuticals, Inc.
Merck & Co., Inc.
Pfizer, Inc.
Pozen
Roxro Pharma, Inc.
Winston Pharmaceuticals, Inc.
Wyeth Consumer Healthcare
Zogenix, Inc.

B. MARKET ANALYTICS

Table 1. US Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 2. US Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2.EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis
Strategic Corporate Developments
Orexo Acquires PharmaKodex
Noxxon Pharma Collaborates with Eli Lilly
Select Players
AstraZeneca Plc (UK)
Bayer AG (Germany)
Ethypharm S.A. (France)
GlaxoSmithKline Plc (UK)
Meda AB (Sweden)
Novartis AG (Switzerland)
UCB S.A. (Belgium)

B. MARKET ANALYTICS

Table 3. European Recent Past, Current & Future Analysis for Anti-Migraine Drugs by Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 4. European Historic Analysis for Anti-Migraine Drugs by Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figure in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 5. European 15-year Perspective for Anti-Migraine Drugs by Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

2A.FRANCE

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis

B. MARKET ANALYTICS

Table 6. French Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 7. French Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2B.GERMANY

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis

B. MARKET ANALYTICS

Table 8. German Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 9. German Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2C.ITALY

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis

B. MARKET ANALYTICS

Table 10. Italian Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 11. Italian Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2D.UNITED KINGDOM

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis
Migraine – Prevalence
Migraine Treatment
Abortive Drugs
List of Abortive Anti-Migraine Drugs Available in the UK
Prophylactic Drugs
List of Prophylactic Anti-Migraine Drugs Available in the UK

B. MARKET ANALYTICS

Table 12. UK Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 13. UK Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2E.SPAIN

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis

B. MARKET ANALYTICS

Table 14. Spanish Recent Past, Current & Future Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 15. Spanish Historic Analysis for Anti-Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2F.REST OF EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Historic Analysis
Ireland

B. MARKET ANALYTICS

Table 16. Rest of Europe Recent Past, Current & Future Analysis for Anti-Migraine Drugs –Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 17. Rest of Europe Historic Analysis for Anti- Migraine Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 57)
Region/CountryPlayers
The United States
Canada
Japan
Europe
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East